Abstract 321P
Background
Ovarian cancer(OC) is the third most common gynaecological cancer in Indian according to Globocan 2020. The majority of patients are diagnosed in advanced stage III and IV. The aim of this study was to evaluate clinical epidemiology and survival outcomes in patients with epithelial ovarian cancer.
Methods
This was a retrospective analysis of patients with epithelial OC who were treated at Asian Institute of Medical Sciences from 1st January 2016 to 31st December 2020. Patient’s sociodemographic characteristics, clinicopathological details like the stage of cancer, treatment received and follow up details was extracted from medical records. All statistical analysis was performed using Microsoft Excel 2016 and R software (Rx 64 version 3.6.2). Survival was estimated by the Kaplan Meier method and compared by the log-rank test.
Results
251 OC patients records were evaluated, epithelial OC constituted 94%(n=235), with a median age 49 years. Majority 81%(n=190) of the patients were in stage III or IV at the time of diagnosis. The main presenting symptoms were abdominal distension 65%(n=153) and gastrointestinal disturbances including pain abdomen 45%(n=106). The most common histologic types were serous 76%(n=179) followed by mucinous carcinoma 18%(n=42). BRCA testing (germline and somatic) was performed in 80 patients. BRCA1/BRCA2 pathogenic or likely pathogenic variant was found in 25% (n=20) patients. Upfront cytoreductive surgery was done only in 28% (n=65). Interval cytoreductive surgery was done in 66%(n=155) patients. Median overall survival for the entire study cohort was 45 months (95% CI, 32 to 47.5). Median overall survival for stage I, II, III, and IV was 62, 53, 38 and 23 months, respectively.
Conclusions
Most of the patients presented in advanced stage of the disease and have poor outcome. Lack of awareness delayed presentation and late diagnosis are resulting in poor outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
581P - The associations between afatinib-related adverse events and survival outcomes in patients with lung cancer
Presenter: Wen-Chen Tang
Session: Poster Display
Resources:
Abstract
582P - Furmonertinib treatment in patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastases: A real-world study
Presenter: Haiyang Chen
Session: Poster Display
Resources:
Abstract
583P - RHBDL2 promotes non-small cell lung cancer metastasis and osimertinib resistance by activating the RAS/MEK/ERK signaling pathway through interaction with FGFR
Presenter: jun Deng
Session: Poster Display
Resources:
Abstract
584P - Upfront aumolertinib for preventing symptomatic central nervous system(CNS) metastases in EGFR-mutant non-small cell lung cancer without baseline CNS metastasis
Presenter: Tangfeng Lv
Session: Poster Display
Resources:
Abstract
585P - Real-world outcomes in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations receiving mobocertinib
Presenter: Tony S.K. Mok
Session: Poster Display
Resources:
Abstract
586P - Clinical validation of a multiplex polymerase chain reaction (mPCR) assay to identify patients (pts) with NSCLC suitable for mobocertinib treatment
Presenter: Caicun Zhou
Session: Poster Display
Resources:
Abstract
587P - Exploring the prevalence and characteristics of human epidermal growth factor receptor 2 (HER2) alterations in non-small cell lung cancer: Analysis from a Malaysian cohort
Presenter: Ning Yi Yap
Session: Poster Display
Resources:
Abstract
588P - First real-world study with HER2 ADC in treating HER2-altered non-small cell lung cancer
Presenter: Kaihua Lu
Session: Poster Display
Resources:
Abstract
590P - A retrospective study of the prevalence and clinical outcomes of KRAS G12C mutated advanced non-small cell lung cancer (NSCLC) in Australian patients (pts)
Presenter: Ben Markman
Session: Poster Display
Resources:
Abstract
591P - The utility of next generation sequencing for KRAS gene variants prevalence in cytological and tissue samples in real-world NSCLC patients: A large single institution real-world study
Presenter: Adam Pluzanski
Session: Poster Display
Resources:
Abstract